Avance® Nerve Graft is processed nerve allograft (human) intended for the surgical repair of peripheral nerve discontinuities to support regeneration across the defect and provides surgeons with a readily available nerve graft to repair peripheral nerves damaged by traumatic injury or removed during a surgical procedure.

The human nerve allograft is decellularized and processed resulting in a surgical implant with the natural structural pathways to guide axon regeneration. Avance® Nerve Graft is available in a range of lengths and diameters, provides the flexibility to be used across joints and handles similarly to an autograft nerve without the comorbidities associated with secondary surgical site.

Avance® Nerve Graft has been successfully implanted at thousands of hospitals and surgery centers across the United States, including military hospitals serving U.S. service men and women.

About AxoGen, Inc.
AxoGen (NASDAQ: AXGN) is a leading regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. AxoGen’s products offer a full suite of surgical nerve reconstruction solutions. Along with Avance® Nerve Graft, these include AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard® Nerve Protector, a bioscaffold used to reinforce a coaptation site, wrap a partially severed nerve or isolate and protect nerve tissue.

Indication for Use: Avance® Nerve Graft is processed nerve allograft (human) intended for the surgical repair of peripheral nerve discontinuities to support regeneration across the defect.

Contraindications: Avance® Nerve Graft is contraindicated for use in any patient in whom soft tissue implants are contraindicated. This includes any pathology that would limit the blood supply and compromise healing or evidence of a current infection.

Regulatory Classification: Avance® Nerve Graft is human tissue for transplantation. It is processed and distributed in accordance with US FDA requirements for Human Cellular and Tissue-based Products (21 CFR Part 1271), State regulations and the guidelines of the American Association of Tissue Banks (AATB). This graft is to be dispensed only by or on the order of a licensed physician.